Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 5/20 | 0.47 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 7/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15663299 | 0.90 | FGFR2 (0.48) | FGFR2DDR2KDRPDGFRAMAPT | |
| SCHEMBL2209315 | 0.89 | MAPT (0.54) | FGFR2KDRPDGFRAMAPTLMNA | |
| SCHEMBL2208527 | 0.88 | KDR (0.42) | FGFR2KDRPDGFRAMAPTLMNA | |
| SCHEMBL2211767 | 0.85 | FGFR2 (0.58) | FGFR2DDR2KDRMAPTLMNA | |
| SCHEMBL15663382 | 0.81 | MAPT (0.54) | FGFR2KDRPDGFRAMAPTLMNA | |
| SCHEMBL15663628 | 0.81 | KDR (0.43) | KDRPDGFRAMAPTLMNAEGFR | |
| SCHEMBL2211601 | 0.79 | DDR2 (0.57) | FGFR2DDR2KDRPDGFRAMAPT | |
| SCHEMBL3701420 | 0.79 | FGFR2 (0.47) | FGFR2DDR2KDRPDGFRAMAPT | |
| SCHEMBL15663432 | 0.79 | MAPT (0.42) | FGFR2DDR2KDRMAPTLMNA | |
| SCHEMBL2211679 | 0.78 | FGFR2 (0.49) | FGFR2DDR2KDRPDGFRAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981891-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-07-19 | — | — | US | claimed |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2010-11-04 | — | — | US | claimed |
| EP-2137177-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | FGFR2 334/4885DDR2 1318/4885KDR 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.